Together, our findings suggest that PARP1/2 dual inhibitors may increase cancer bone metastasis through PARP2-dependent regulation of IMCs, and cause bone loss through PARP1/2-dependent regulation of osteoclasts (Fig. 4i). This evidence concerns the gene PARP1 and cancer.